Comparison of the Efficacy and Safety of Latanoprost 0.005% Compared to Brimonidine 0.2% or Dorzolamide 2% When Added to a Topical β-Adrenergic Blocker in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

ABSTRACT

The purpose of this study was to evaluate the ocular hypotensive efficacy and safety of latanoprost 0.005% (Xalatan®, Pharmacia & Upjohn), brimonidine (Alphagan®, Allergan), and dorzolamide (Trusopt®, Merck Inc.) when added to a β-blocker in patients with ocular hypertension or primary open-angle glaucoma.

This was a multicenter, retrospective analysis which included all reviewed patient records in which latanoprost, brimonidine or dorzolamide were added to a β-blocker for at least three months. Patients who were treated for less than three months, who failed therapy due to ineffectiveness of the medicine or an adverse event also were included.

The study included 141 patients. Latanoprost (n = 50) showed an intraocular pressure of 16.7 ± 3.3 mm Hg (−6.3 ± 4.1 mm Hg, P < 0.001), brimonidine (n = 24) 17.4 ± 4.9 mm Hg (−4.2 ± 4.5 mm Hg, P < 0.001), and dorzolamide (n = 67) 20.1 ± 6.1 mm Hg (−3.1 ± 5.1 mm Hg, P < 0.001) at three months. A significant difference was observed in the absolute level of intraocular pressure (P < 0.005) and the change from baseline between groups (P < 0.005) at three months. A significant difference was observed between groups in the success rate of therapy between latanoprost (70%), brimonidine (58%) and dorzolamide (40%) (P = 0.008). No significant differences were observed between groups for rate or type of adverse events leading to discontinued therapy.

This study showed that latanoprost, when added to β-blockers, compares favorably in ocular hypotensive efficacy and is similar in safety to brimonidine and dorzolamide.